Skip to main content

AS/Spondyloarthritis

RheumNow Podcast square
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-OPTIMISE:…
Video: The PsA SpA Paradox of Choice

Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized T

Dr. John Cush RheumNow

3 months 2 weeks ago
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021

https://t.co/ocyR4ka8z

Dr. John Cush RheumNow

3 months 2 weeks ago
Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021 https://t.co/ocyR4ka8zO https://t.co/DxHjM0stKo
audience learn
Here are a few notable presentations from Day 3. BEAT- LUPUS Trial: OP0129 – I would consider this a pilot trial as it only included 52 patients with active SLE, but the gist was that active SLE…
COVID vaccine vials
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress,…
RT @MeralElRamahiMD: OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASD

Meral K. El Ramahi, MD MeralElRamahiMD

3 months 2 weeks ago
OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
RT @MeralElRamahiMD: ⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema

Meral K. El Ramahi, MD MeralElRamahiMD

3 months 2 weeks ago
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
×